<DOC>
	<DOCNO>NCT02500667</DOCNO>
	<brief_summary>The present study design assess effect Rifampin pharmacokinetics N91115 healthy subject .</brief_summary>
	<brief_title>A Drug-Drug Interaction Study N91115 +/- Rifampin Healthy Adult Subjects</brief_title>
	<detailed_description>This study assess effect multiple oral dose administration rifampin steady state plasma pharmacokinetics ( PK ) N91115 healthy subject . Eligible subject ( n=15 ) receive oral dos N91115 twice daily ( approximately every 12 hour ) Study Days 1 morning Day 13 . On Study Days 8 12 , rifampin administer 600 mg daily add N91115 regimen . Study subject monitor safety house clinical research unit ( CRU ) discharge Day 14 . Pharmacokinetics follow Study Day 1 Study Day 14 . A follow-up phone call make Day 20 ( 1 day ) . Participation individual subject may last approximately 48 day time screen end-of-study follow-up call .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Subject voluntarily agree participate study ; sign IRBapproved inform consent Subject healthy determine screen medical evaluation ( include limit medical history , physical examination clinical laboratory evaluation ) Subject Caucasian Female subject must nonchildbearing potential postmenopausal Male subject must agree use condom spermicide refrain sperm donation Day 1 30 day post last dose vasectomy least 6 month prior screen Subject nonsmoker Subject body weight &gt; 45 kg BMI 18 32 kg/m2 Subject clinically significant vital sign find screen Day 1 , per investigator 's judgment Subject clinically significant abnormal finding 12lead ECG , per investigator 's judgment , screen Subject clinically significant history evidence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , neurological , immunological , psychiatric disorder ( ) Subject abnormal 12lead ECG screen per protocol Subject disorder would interfere absorption , distribution , metabolism excretion drug Subject concurrent disease condition , opinion investigator , would make subject unsuitable participation clinical study Subject current alcohol abuser and/or history illicit drug abuse within 1 year prior dose Subject positive screening test Hepatitis B surface antigen , Hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody Subject unwilling refrain consumption coffee caffeinecontaining food beverage Day 1 discharge Day 14 Subject unwilling abstain use alcohol beverage Day 1 discharge Day 14 Subject donate blood ( &gt; 500 mL ) blood product within 56 day prior Day 1 Subject use overthecounter ( OTC ) medication ( include vitamin ) Day 7 , prescription medication , herbal remedy Day 14 endofstudy followup call . By exception , acetaminophen â‰¤ 1000 mg/day permit except within 48 hour prior Day 1 hormone replacement therapy ( HRT ) allow throughout study Subject use investigational drug within 30 day prior Day 1 dose Subject history bleeding disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>N91115</keyword>
	<keyword>Rifampin</keyword>
	<keyword>drug interaction</keyword>
	<keyword>Cavosonstat</keyword>
</DOC>